Search results for "From ACP Journal Club"


 
Results 81 - 90 of about 131 for "From ACP Journal Club".
Sort by: Relevance | Newest | Oldest

DPP-4 inhibitors are less effective than metformin for reducing hemoglobin A1c

A meta-analysis of randomized controlled trials comparing dipeptidyl peptidase-4 (DPP-4) inhibitors to metformin and other drugs found that DPP-4 monotherapy is less effective.
https://diabetes.acponline.org/archives/2012/08/10/7.htm
10 Aug 2012

Bariatric surgery improved HbA1c more than intensive medical therapy in obese patients with uncontrolled type 2 DM

Longer-term outcomes show that adding Roux-en-Y gastric bypass (RYGB) or sleeve gastrectomy to intensive medical therapy enabled more obese, type 2 diabetes patients to maintain glycemic control.
https://diabetes.acponline.org/archives/2014/09/12/6.htm
12 Sep 2014

Review: In type 2 diabetes, sodium–glucose cotransporter 2 inhibitors do not increase major CV events or mortality

The meta-analysis included 37 trials that compared canagliflozin, dapagliflozin, or empagliflozin to placebo or other active antidiabetic treatments.
https://diabetes.acponline.org/archives/2017/02/10/6.htm
10 Feb 2017

In overweight or obese patients with diabetes, a lifestyle intervention increased weight loss at 8 years

Receiving an intensive lifestyle intervention (ILI) rather than traditional diabetes support and education (DSE) increased weight loss in about 5,000 middle-aged adults with type 2 diabetes.
https://diabetes.acponline.org/archives/2014/07/11/5.htm
11 Jul 2014

Review: Bariatric surgery improves weight and glycemia in nonmorbidly obese adults with diabetes

A review of 3 randomized controlled trials found that surgical treatment increased weight loss and improved diabetes-related outcomes more than nonsurgical treatment in moderately obese patients.
https://diabetes.acponline.org/archives/2013/11/08/7.htm
8 Nov 2013

In type 1 diabetes, adding liraglutide to insulin increased hypoglycemia and hyperglycemia with ketosis

The study authors concluded that the negative effects observed would limit clinical use of liraglutide in patients with type 1 diabetes.
https://diabetes.acponline.org/archives/2017/01/13/6.htm
13 Jan 2017

Meta-analysis: Self-monitoring in non-insulin-treated type 2 diabetes improved HbA1c by 0.25%

A meta-analysis of randomized controlled trials of patients with non–insulin-treated type 2 diabetes found that six months of self-monitoring blood glucose reduced hemoglobin A1c levels by 0.25% more than usual care.
https://diabetes.acponline.org/archives/2012/07/13/8.htm
13 Jul 2012

Semaglutide reduced a composite of CV events at two years in patients with type 2 diabetes and high CV risk

Semaglutide, a new once-weekly glucagon-like peptide-1 (GLP-1) analogue, reduced cardiovascular (CV) events compared to placebo, according to a manufacturer-sponsored study.
https://diabetes.acponline.org/archives/2017/02/10/7.htm
10 Feb 2017

In patients with type 2 diabetes and high CV risk, liraglutide reduced a composite CV outcome at a median 3.8 y

The study's primary composite outcome was first occurrence of death from cardiovascular (CV) causes, nonfatal (including silent) myocardial infarction, or nonfatal stroke.
https://diabetes.acponline.org/archives/2016/11/11/6.htm
11 Nov 2016

In type 2 diabetes, weekly semaglutide reduced HbA1c and increased weight loss more than weekly exenatide ER

Exenatide is still an effective alternative for patients who cannot tolerate semaglutide due to gastrointestinal adverse events, noted the ACP Journal Club commentary.
https://diabetes.acponline.org/archives/2018/05/11/7.htm
11 May 2018

Result Page: Prev   4   5   6   7   8   9   10   11   12   13   Next